Of the previously proposed markers mostly revealed in pathological groups in the present study, increased levels of AHSG and HPT in all glomerulopathies coincide well with the findings of other studies, while the increases in CERU, F2, A2MG, and ADIPO were previously shown mainly for IgAN (as reviewed in [10]), but this group was not considered in the present study. This evidence concerns the gene AHSG and lipoprotein glomerulopathy.